期刊文献+

乳癌组织中PTEN的表达 被引量:1

Expression of PTEN in breast carcinoma tissue
下载PDF
导出
摘要 目的:探讨乳癌组织中第10号染色体缺失的磷酸酶和张力蛋白同源物基因(PTEN)的表达及其意义。方法:采用免疫组织化学SP方法,检测74例乳癌组织(TNM分期:Ⅰ期18例,Ⅱ期31例,Ⅲ期25例。有腋窝淋巴结转移40例,无转移者34例)和20例正常乳腺组织中PTEN蛋白的表达水平。另取20例正常乳腺组织为对照。结果:乳癌组织中PTEN蛋白的阳性率和阳性强度均低于正常乳腺组织(P<0.01);腋淋巴结转移组的乳癌组织中PTEN蛋白阳性率明显低于无淋巴结转移组(P<0.05);随着临床分期的增高,PTEN蛋白阳性表达率呈下降趋势(P<0.05);PTEN表达水平与患者年龄、肿瘤大小无关。结论:PTEN蛋白的异常表达与乳癌的发生发展密切相关,通过检测PTEN蛋白的表达,对估计乳癌的预后有一定的意义。 Aim: To investigate the expression of PTEN and its clinical significance in breast carcinoma tissue. Methods: Expression of PTEN in 74 cases of breast carcinoma and 20 normal breast tissue was detected using immunohistochemistry SP method. Results: The positive rate and expressive intensity of PTEN protein in breast carcinoma tissue were lower than those in normal breast tissue ( P 〈 0.01 ) ; the positive rate of PTEN in axillary lymph node metastasis group was lower than that in the group without axillary lymph node metastasis ( P 〈 0.05 ) ; the positive rate of PTEN was correlated with clinical stage ( P 〈 0.05 ) , and with the increasing of clinical stage, the positive rate of PTEN was declined, but it was not correlated with age and tumor size. Conclusion : Abnormal expression of PTEN is closely associated with the development of breast carcinoma. It is helpful to assess the prognosis of breast carcinoma by detecting the expression of PTEN.
出处 《郑州大学学报(医学版)》 CAS 北大核心 2005年第6期1112-1114,共3页 Journal of Zhengzhou University(Medical Sciences)
关键词 乳腺肿瘤 基因表达 PTEN breast neoplasm gene expression PTEN
  • 相关文献

参考文献8

  • 1Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidatate tumor suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancer.Nat Genet, 1997,15 (4) :356
  • 2王玉岳,崔全才.PTEN研究的新进展[J].国外医学(分子生物学分册),2003,25(3):150-152. 被引量:3
  • 3Li J,Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast and prostate cancer. Science, 1997,275 (5 308): 1 943
  • 4Li Y, Podsvpanina K, Liu X ,et al. Deficiency of PTEN accelerate mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol ,2001,2(1):2
  • 5Perren A ,Weng LP, Boag AH, et al. Immuohistochemical evidence of loss of PTEN expression in primary ductual adenocarcinoma of the breast. Am J Pathol,1999,155(4) :1 253
  • 6Starnbolic V,Tsao MS,Macpherson D,et al. High incidence of breast and endometrial neoplasia resembling human cowdlen syndrome in PTEN +/- mice. Cancer Res,2000,60(13) :3 605
  • 7Sano T, Lin H, Chen X, et al. Differential expression of MMAC1/PTEN in glioblastoma multiforme; relationship to localization and prognosis. Cancer Res, 1999,59 ( 8 ): 1 820
  • 8王知力,郭双平,王文亮.PTEN基因的研究进展[J].临床与实验病理学杂志,2001,17(4):339-341. 被引量:16

二级参考文献21

  • 1[1]Leslie NR et al. Biochem J, 2000; 346:827
  • 2[2]Li DM et al. Cancer Research, 1997; 57:2124
  • 3[3]Tolkacheva T et al. Oncogene, 2000; 19:680
  • 4[4]Yan W et al. J Biol Chem, 2000; 275:21477
  • 5[5]Gao X et al. Dev Biol, 2000; 221:404
  • 6[6]Kwabi AB et al. Cell Biol, 2000; 19:301
  • 7[7]Yokoyama Y et al. Int J Mol Med, 2000; 6:47
  • 8[8]Teng DH et al. Cancer Res, 1997; 57:5221
  • 9[9]Mutter GL et al. J Clin Endocrinol Metab, 2000; 85:2334
  • 10[10]Gimm O et al. Am J Pathol, 2000; 156:1693

共引文献17

同被引文献17

  • 1O'MALLEY F P, CHIA S, TU D, et al. Topoisomerase Ⅱ al- pha and responsiveness of breast cancer to adjuvant chemother- apy[J]. J Natl Cancer Inst, 2009, 101(9): 644-650.
  • 2TUBBS R, BARLOW W E, BUDD G T, et al. Outcome of pa- tients with early-stage breast cancer treated with doxorubicin- based adjuvant chemotherapy as a function of HER2 and TOP2A status[J]. J Clin Oncol, 2009, 27(24):3881-3886.
  • 3COBO M, ISLA D, MASSUTI B, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression., a phase Ⅲ trial in non-small-cell lung canc- er[J]. J Clin Oncol, 2007, 25(19):2747-2754.
  • 4St~VE P, ISAAC S, TRI~DAN O, et al. Expression of class Ⅲ β-tubulin is predictive of patient outcome in patients with non- small cell lung cancer receiving vinorelbine-based chemotherapy [J]. Clin Cancer Res, 2005, 11(15):5481-5486.
  • 5ARRIOLA E, MARCHIO C, TAN DSP, et al. Genomic anal- ysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell linesl-J]. Lab Invest, 2008, 88(5):491-503.
  • 6SUN JM, HAN J, AHN JS, et al. Significance of thymidylate synthase and thyroid transcription factor 1 expression in pa- tients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy[J]. J Thorac Oncol, 2011, 6 (8) : 1392-1399.
  • 7SIMON G, SHARMA A, LI X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in ad- vanced non-small-cell lung cancer[J]. J Clin Oncol, 2007, 25 (19) :2741-2746.
  • 8SLAMON DJ, PRESS MF. Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers[J]. J Natl Cancer Inst, 2009, 101(9) : 615-618.
  • 9BRASE JC, SCHMIDT M, FISCHBACH T, et al. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene am- plification, RNA levels, and protein expression and their influ- ence on prognosis and prediction[J]. Clin Cancer Res, 2010, 16(8) :2391-2401.
  • 10HASEGAWA S, MIYOSHI Y, EGAWA C, et al. Prediction of response to docetaxel by quantitative analysis of class I and Ⅲβ-tubulin isotype mRNA expression in human breast cancers [J]. Clin Cancer Res, 2003, 9(8):2992-2997.

引证文献1

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部